Activity ID
15383Expires
December 31, 2027Format Type
LiveCME Credit
1Fee
$0CME Provider: Clinical Care Options, LLC
Description of CME Course
This educational program aims to strengthen clinician competence in mechanism-based pharmacotherapy for schizophrenia by reviewing emerging evidence and supporting advanced clinical reasoning as new, non‑dopaminergic treatment options evolve.
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Psychiatry and Neurology
Commercial Support?
YesNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
· Identify unmet needs in the management of schizophrenia with traditional antidopaminergic antipsychotics and the potential for safety and efficacy improvements with novel agents.
· Apply an understanding of the mechanisms of action and pharmacokinetic characteristics of new and emerging schizophrenia treatments in counseling patients on dosing, administration, and food requirements.
· Integrate muscarinic pharmacology into advanced clinical decision-making and treatment planning for schizophrenia.
Competencies
Medical Knowledge
CME Credit Type
AMA PRA Category 1 Credit
Practice Setting
Academic Medicine, Inpatient, Outpatient, Rural, Urban, VA/Military
